Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
61 articles
November 20265
Diagnostic yield and early outcomes of radical prostatectomy without prior histopathologic diagnosis: a single-arm systematic review and meta-analysis.
This single-arm systematic review and random-effects meta-analysis assessed radical prostatectomy without prior histopathologic confirmation in adult men with high clinical suspicion of clinically significant prostate…
Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial.
This prospective, single-arm phase II trial evaluated sequential anlotinib and radioiodine (RAI) in patients with measurable distant metastatic differentiated thyroid cancer (DTC).
Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.
This prospective clinical trial assessed a personalized sequence of intraarterial then intravenous 177Lu-DOTATATE in 10 adults with progressive, nonresectable, liver-dominant metastatic gastroenteropancreatic…
Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas.
This phase I, first-in-human study evaluated the safety, biodistribution, dosimetry, and preliminary efficacy of the dual-targeting radioligand 177Lu-LNC1009 in nine patients with advanced solid tumors and positive…
Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.
This prospective phase 2 trial compared CD38-targeted 89Zr-DFO-daratumumab immuno-PET/CT with standard-of-care 18F-FDG PET/CT in 60 participants with multiple myeloma.
October 202616
Ectopic cushing syndrome caused by intestinal neuroendocrine tumors: a systematic review.
This systematic review characterized ectopic Cushing syndrome caused by intestinal neuroendocrine tumors using published case reports and an illustrative unpublished case. It identified 24 published cases.
Imaging Features and Prognosis of Anti‑Sez6l2 Encephalitis: A Longitudinal Cohort Study and Literature Review.
This longitudinal cohort study and systematic review examined clinical features, multimodal imaging, and treatment response in anti-Sez6l2 encephalitis.
Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer: A Systematic Review.
This PRISMA-guided systematic review assessed novel imaging for detecting muscle invasion and nodal disease before surgical management of invasive bladder cancer. It included 33 studies encompassing 4,689 patients.
The Clinical Significance of Hyperkinetic Biliary Dyskinesia on HIDA Scan: A Systematic Review and Meta-analysis.
This systematic review and meta-analysis assessed outcomes after cholecystectomy in patients with biliary-type pain and gallbladder ejection fraction (EF) ≥80% on CCK-stimulated HIDA scans.
Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).
This multicenter phase I dose-escalation and dose-expansion study evaluated [177Lu]lutetium-dotatate plus oral triapine in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti-PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer.
This phase I dose-escalation and expansion study evaluated fractionated and repeated-cycle 225Ac-J591 in patients with progressive metastatic prostate cancer resistant to androgen pathway modulation.
Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT).
This prospective pilot study enrolled 30 patients with WHO grade 3 or 4 high-grade glioma receiving postoperative radiotherapy.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
This individual participant data meta-analysis examined amyloid PET scans from 49,227 participants across 53 studies to establish Centiloid positivity cutoffs for Alzheimer disease diagnosis.
¹⁸F-sodium fluoride PET/CT as a complementary measure of osteoblastic disease burden in axial spondyloarthritis: a prospective exploratory study.
This prospective exploratory imaging study assessed whether sacroiliac joint (SIJ) ¹⁸F-sodium fluoride PET/CT could complement MRI in 43 adults with chronic low back pain classified as radiographic axial…
First-in-human dosimetry and biodistribution of [ 89 Zr]Zr-oxine-labeled autologous leukocytes using PET/CT.
This prospective first-in-human clinical trial evaluated the safety, biodistribution and radiation dosimetry of [89Zr]Zr-oxine-labeled autologous leukocytes in four healthy adult women.
Clinical Trial Protocol for LPS-Boost: Intensified [ 177 Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
This multicenter, open-label phase 2 trial investigates an intensified treatment schedule of [177Lu]Lu-PSMA-617 for 45 patients with metastatic castration-resistant prostate cancer (mCRPC) and low PSMA expression.
Tumor and Organ Dose Estimates from 177 Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
The RESIST-PC Phase 2 trial assessed dosimetry of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. A total of 48 patients were analyzed, receiving either 6.0 or 7.4 GBq per cycle.
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
The OPTIMAL-PSMA study is a Phase 2, open-label, randomized controlled trial evaluating the safety and efficacy of a dose-intensified regimen of [177Lu]Lu-PSMA-597 versus standard dosing in 120 patients with metastatic…
First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.
This first-in-human, open-label, single-arm Phase I study evaluated the safety and pharmacokinetics of 211At-meta-astatobenzylguanidine (211At-MABG) in 10 patients with unresectable or metastatic pheochromocytomas or…
Follow-Up 18F-Fluorodeoxyglucose Positron Emission Tomography in Treated Patients With Giant Cell Arteritis: A Systematic Review and Metaanalysis.
This systematic review and meta-analysis evaluated the use of 18F-fluorodeoxyglucose (FDG) PET to monitor disease activity in patients with large-vessel giant cell arteritis (LV-GCA) who showed clinical improvement…
[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.
[18F]RCCB6 PET/CT was evaluated in a single-center phase II trial for detecting metastases in clear-cell renal cell carcinoma (ccRCC).
September 20263
First systematic mapping of non-target [68Ga]Ga-DOTANOC uptake across anatomical sites and etiologies.
This systematic review analyzed 76 studies involving 542 patients to map non-target [68Ga]Ga-DOTANOC uptake across various anatomical sites and etiologies.
PD-L1 PET/CT imaging with 18 F-BMS-986,229 and 18 F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer.
This multicenter clinical trial evaluated baseline PD-L1 PET/CT with two tracers in patients with stage IV non-small cell lung cancer (NSCLC), comparing tumor uptake with biopsy PD-L1 immunohistochemistry (IHC) and…
Evaluating the Clinical Utility of TSPO-PET in MS and the Influence of Methodological Heterogeneity: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis evaluated TSPO-PET imaging in multiple sclerosis (MS) patients compared to healthy controls.
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.